- Home
- ESP vs MGNX Comparison
ESP vs MGNX Comparison
Compare ESP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESP
- MGNX
- Stock Information
- Founded
- ESP 1928
- MGNX 2000
- Country
- ESP United States
- MGNX United States
- Employees
- ESP N/A
- MGNX N/A
- Industry
- ESP Industrial Machinery/Components
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ESP Technology
- MGNX Health Care
- Exchange
- ESP Nasdaq
- MGNX Nasdaq
- Market Cap
- ESP 84.1M
- MGNX 97.2M
- IPO Year
- ESP N/A
- MGNX 2013
- Fundamental
- Price
- ESP $36.39
- MGNX $1.41
- Analyst Decision
- ESP
- MGNX Hold
- Analyst Count
- ESP 0
- MGNX 9
- Target Price
- ESP N/A
- MGNX $5.33
- AVG Volume (30 Days)
- ESP 26.2K
- MGNX 378.7K
- Earning Date
- ESP 05-12-2025
- MGNX 05-13-2025
- Dividend Yield
- ESP 2.73%
- MGNX N/A
- EPS Growth
- ESP 39.20
- MGNX N/A
- EPS
- ESP 2.67
- MGNX N/A
- Revenue
- ESP $45,965,588.00
- MGNX $154,050,000.00
- Revenue This Year
- ESP N/A
- MGNX N/A
- Revenue Next Year
- ESP N/A
- MGNX $45.52
- P/E Ratio
- ESP $13.69
- MGNX N/A
- Revenue Growth
- ESP 29.60
- MGNX 255.31
- 52 Week Low
- ESP $20.20
- MGNX $0.99
- 52 Week High
- ESP $39.41
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- ESP 63.52
- MGNX 39.88
- Support Level
- ESP $34.90
- MGNX $1.30
- Resistance Level
- ESP $39.41
- MGNX $1.58
- Average True Range (ATR)
- ESP 1.41
- MGNX 0.11
- MACD
- ESP -0.04
- MGNX -0.02
- Stochastic Oscillator
- ESP 64.29
- MGNX 17.65
About ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.